Table 1.
Patient Demographics
| Pt # | Donor Type | Age at Bortezomib Protocol | Sex | HLA Mismatch A, B, DR (DQ) | Tx# | cPRA% HLA Class I/Class II | Etiology of ESRD | MNA |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 1 | DD | 5y | M | 2,1,2 (2) | 1 | 0/0 | Hypoxia | No |
| 2 | DD | 17y | M | 2,2,2 (2) | 1 | 0/0 | ANCA GN | Yes |
| 3 | DD | 15y | M | 1,2,2 (2) | 1 | 0/0 | Indomethacin Toxicity | Yes |
| 4 | LRD | 14y | M | 1,1,1 (1) | 1 | 0/0 | Congenital Nephrotic Syndrome | Yes |
| 5 | LRD | 14y | M | 1,2,1 (2) | 1 | 0/0 | Congenital Nephrotic Syndrome | Yes |
| 6 | DD | 18y | F | 2,2,1 (1) | 2 | 84/43 | Neurogenic Bladder | Yes |
| 7 | DD | 19y | M | 1,2,2 (2) | 1 | 0/0 | Dysplasia | Yes |
Pt patient, DD deceased donor, LRD living related donor, y year, M male, F female, HLA human leukocyte antigen, Tx transplant, cPRA calculated panel reactive antibody, ESRD end stage renal disease, ANCA GN anti-neutrophil cytoplasmic antibody glomerulonephritis, MNA medication nonadherence